The Pharmacy Times® Diabetes Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of chronic diseases that result in high blood glucose.
May 14th 2024
According to the results, approximately 82% of adults said they have heard at least a little about GLP-1 medications and 32% said they have heard a lot.
The Emerging Treatment Landscape for Hemophilia A and the Valuable Role of the Specialty Pharmacist
1.5 Credits / Endocrinology Diabetes & Metabolism
View More
Improving Pharmacists' Knowledge of Endometrial Cancer and Solutions for Equity and Medication Access
1.5 Credits / Endocrinology, Diabetes & Metabolism, Oncology
View More
Delving Into the Latest Integrated Continuous Glucose Monitoring Devices: An Interdisciplinary Approach With Case Discussions to Enhance Diabetes Care
1.5 Credits / Endocrinology Diabetes & Metabolism
View More
Delving Into the Latest Integrated Continuous Glucose Monitoring Devices: An Interdisciplinary Approach With Case Discussions to Enhance Diabetes Care (Pharmacy Technician Cre...
1.5 Credits / Endocrinology Diabetes & Metabolism
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Diabetes Management With Integrated Continuous Glucose Monitoring Devices: Pharmacist Best Practices for Individualizing Treatment
0.75 Credit / Endocrinology Diabetes & Metabolism
View More
The Role of Integrated Continuous Glucose Monitoring in Improving Clinical Outcomes in Diabetes
0.75 Credit / Endocrinology Diabetes & Metabolism
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Continuous Glucose Monitoring in Diabetes Care: Examining the Value and Addressing Barriers to Access
3.5 Credits / Endocrinology, Diabetes & Metabolism
View More
Introduction to Chronic Kidney Disease in People Living With Type 2 Diabetes: Combating Disease Progression and Complications
1.0 Credit / Endocrinology, Diabetes, and Metabolism, Nephrology
View More
Examining Current and Emerging Therapies to Slow Progression of Chronic Kidney Disease
1.0 Credit / Endocrinology, Diabetes, and Metabolism, Nephrology
View More
Tailoring Recommendations for People Living With Type 2 Diabetes and Chronic Kidney Disease: The Role of the Pharmacist
1.0 Credit / Endocrinology, Diabetes, and Metabolism, Nephrology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
The Utilization of SGLT2 Inhibitors in the Treatment of Cardiovascular Disease, Diabetes, and Chronic Kidney Disease
1.5 Credits / Cardiology; Endocrinology, Diabetes & Metabolism; Nephrology
View More
Adverse Events Among Patients With Type 2 Diabetes, COVID-19 Treated With Dapagliflozin
July 8th 2021Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed what some of the adverse events experienced by patients were, and how patients were able to handle them.
Watch
Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses how the results from the phase 3 trial evaluating an investigational 2 mg dose of semaglutide could change treatment options for patients with type 2 diabetes.
Watch
Assessing the Use of Dapagliflozin in Patients With Type 2 Diabetes Hospitalized With COVID-19
July 5th 2021Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed how the phase 3 DARE-19 trial was conducted to assess dapagliflozin in patients with type 2 diabetes hospitalized with COVID-19.
Watch
Safety Profile of Dapagliflozin Among Patients With Type 2 Diabetes Hospitalized With COVID-19
July 2nd 2021Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the safety profile of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19 during the DARE-19 trial.
Watch
Assessing Adverse Events From Investigational Dose of Semaglutide Injection for Type 2 Diabetes
July 2nd 2021Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the adverse events experienced by patients during the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes.
Watch
Efficacy, Safety of an Investigational Dose of Semaglutide Injection in Adults With Type 2 Diabetes
June 30th 2021Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the findings around the efficacy and safety of the 2 mg dose of semaglutide for the treatment of type 2 diabetes.
Watch